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Abstract
Objective: To investigate parents’ views about deferred consent to inform management of trial disclosure after a child’s
death.
Methods: A postal questionnaire survey was sent to members of the Meningitis Research Foundation UK charity, whose
child had suffered from bacterial meningitis or meningococcal septicaemia within the previous 5 years. Main outcome
measures were acceptability of deferred consent; timing of requesting consent; and the management of disclosure of the
trial after a child’s death.
Results: 220 families were sent questionnaires of whom 63 (29%) were bereaved. 68 families responded (31%), of whom 19
(28%) were bereaved. The majority (67%) was willing for their child to be involved in the trial without the trial being
explained to them beforehand; 70% wanted to be informed about the trial as soon as their child’s condition had stabilised.
In the event of a child’s death before the trial could be discussed the majority of bereaved parents (66% 12/18) anticipated
wanting to be told about the trial at some time. This compared with 37% (18/49) of non-bereaved families (p=0.06).
Parents’ free text responses indicated that the word ‘trial’ held strongly negative connotations. A few parents regarded gaps
in the evidence base about emergency treatments as indicating staff lacked expertise to care for a critically ill child.
Bereaved parents’ free text responses indicated the importance of individualised management of disclosure about a trial
following a child’s death.
Discussion: Deferred consent is acceptable to the majority of respondents. Parents whose children had recovered differed
in their views compared to bereaved parents. Most bereaved parents would want to be informed about the trial in the
aftermath of a child’s death, although a minority strongly opposed such disclosure. Distinction should be drawn between
the views of bereaved and non-bereaved parents when considering the acceptability of different consent processes.
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Introduction
When a child is admitted to hospital in an emergency situation
his/her parents (or care providers) need to be able to draw some
reassurance that the child is in the ‘best possible hands’ and
receiving the ‘right treatment’. Yet many emergency treatments
have crept in to common use without a robust evidence base [1].
Few clinicians or parents would disagree that clinical research in
emergency, life-threatening conditions is required to improve
patient outcomes; however there are many ethical issues that need
to be addressed when designing a randomised controlled trial
(RCT) to be conducted under these circumstances.
In 2004 the European Clinical Trials Directive [2], incorporat-
ing the ICH Harmonised Tripartite Guideline for Good Clinical
Practice (ICH GCP) on clinical research was translated in to law
across its member states [3]. This set valid informed consent as the
cornerstone of experimental research involving human beings.
However, the Directive made no provision for consent in
emergency situations, thus creating a formidable barrier to
research in this setting. Member states were forced either to
operate at variance with the Directive or to accept restriction of
such research. Internationally guidelines on emergency consent
vary or are not specifically addressed [4]. The UK amended its
legislation in 2006 to incorporate a deferred consent process in
emergency situations for incapacitated adults [5] and in 2008 for
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required urgently; (ii) urgent action is required for the purposes of
the trial; (iii) it is not reasonably practicable to obtain consent
prospectively; and (iv) an ethics committee has given approval to
the procedure under which the action is taken.
The process of deferred consent allows patients to be included in
research studies without obtaining their prior informed consent or
that of their parent/carer (in the case of a legal minor), but
requires that informed consent is obtained as soon as possible for
continued study participation. In the US consent waivers are used,
whereby researchers are not required to obtain patient consent at
any stage provided that the research is granted ethical approval
following public disclosure and community consultation [7]. In this
context, community consultation may be regarded as a mandatory
formalisation of patient and public involvement. However, the
requirements for such consultation are unclear and this lack of
guidance has been described as a barrier to emergency research in
the US [8]. Deferred consent raises additional ethical dilemmas
not present with consent waivers, such as: how and when to inform
parents that their child has been included in a trial; how to handle
the situation where a child dies before consent can be obtained but
has been included in the trial; and the potential that the decision to
decline is associated with a child’s poor outcome thereby creating
bias in the trial results and conclusions [9–11].
Many treatments are routinely administered in children with
life-threatening conditions infection, without a strong evidence
base for their use [12]. Historically this is an extremely difficult
situation in which to perform clinical trials given the considerable
complexities involved in seeking parental consent in the emergen-
cy care setting, when children are critically ill and their parents are
profoundly anxious and distressed. In this context, the method for
seeking consent needs to avoid delaying patient treatment, whilst
being as acceptable as possible to parents. Deferred consent has
been approved to address these requirements, yet little is known
about how parents view it or how to provide trial disclosure. We
therefore carried out a survey with parents to explore their
perspective on the proposed use of deferred consent in a double
blind randomised controlled trial (RCT) which was being
developed in the UK.
The RCT would compare the effectiveness of two treatments
currently in widespread use and considered safe for children with
presumed severe sepsis requiring emergency resuscitation and
immediate treatment. In such a trial it may be harmful to delay a
child’s treatment in order to seek prospective parental consent for
the child’s involvement in the trial. To explore how to minimise
the anxiety and distress that may be associated with involvement in
a clinical trial in this intensely emotional setting, the views of
parents who had first-hand experience of their child receiving
emergency treatment for severe sepsis were investigated. Parents’
perceptions of deferred consent and opinions about how
practitioners should make requests for deferred consent when a
child had died before the trial could be discussed were sought.
Methods
A postal survey was conducted to inform the design of a
proposed double blind RCT within the UK.
The sample was drawn from a database of members of the
Meningitis Research Foundation (MRF), a UK medical research
charity which provides support to families affected by meningitis
and septicaemia.
220 families were invited to take part in the survey that had a
child admitted as an emergency within the last five years with
bacterial meningitis (BM) or meningococcal septicaemia (MS).
Had the proposed trial been running at the time of their child’s
illness they would have received one of the treatments without
their parents’ prior consent. Advice received from the UK Central
Office for Research Ethics Committees was that ethical approval
was not required for a survey of attitudes towards an RCT.
Survey
The mailing included an invitation letter to explain the survey, a
document describing the proposed trial emphasizing why the trial
was needed, the difficulties of conducting a trial in this setting, and
explaining that both treatments are in widespread use outside of
the trial and two scenarios (appendix S1).
The two scenarios in the survey were set in the context of the
proposed trial and its design:
Scenario A referred to a ‘‘child of mine’’ who needed
emergency treatment. Because of the intensely sensitive
nature of child death, we phrased Scenario B in more
general terms, ‘‘If a child could not be resuscitated and
unfortunately died in the emergency department…’’.
A set of closed and open ended items followed the scenarios.
The closed items in the survey had five response options ranging
from strongly disagree to strongly agree.
The invitation letter, description of the proposed trial, scenarios
and survey were developed by the study team, which included a
lay person, clinician, psychologist, statistician, and trial manager.
A decision was made in agreement with the MRF to accept no
response to the initial contact as indicating unwillingness to take
part.
Analysis
The quantitative data from the closed items were analysed using
simple descriptive statistics and the chi-square test for trend; exact
tests were used as appropriate. Consistency of responses was
considered by cross tabulations of responses between questions as
an indication the survey was understood.
Analysis of the qualitative data, which comprised parents’ free
text responses to the open ended items, drew on the principles of
thematic analysis [13] and used both inductive and deductive
approaches [14]. DS led the analysis, producing a coding frame
that was iteratively developed to represent and code the data, as
informed by BY’s and DS’s multiple readings of all free text
responses and detailed discussions of the developing analysis.
Procedural measures to ensure the quality of the analysis [15,16]
included attending to deviant cases and examining alternative
formulations of the data. We documented the analysis, describing
the key themes, sub-themes and areas of tension including
extensive data extracts. Investigator triangulation involved PW,
SN and CG reading and commenting upon this document to
further refine and ‘test’ the analysis. The involvement of
investigators with different perspectives in this process avoided
any single perspective dominating and helped to connect the
conclusions with practice and research. To evidence our
interpretations verbatim excerpts from parents’ free text responses
are presented accompanied with their identification numbers; ‘B’
indicates bereaved parents’ and ‘R’ indicates parents’ whose child
had recovered. Square brackets […] signify omitted text while
[text] indicates text that we added for clarification.
The results are presented according to overall themes within
the survey grouped by whether the parent was bereaved or
whether the child recovered. The qualitative findings are
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contextualize and illuminate the quantitative responses.
Results
Of the 220 families who were sent the postal survey 63 (29%)
were bereaved. Sixty eight families responded, of which 19 (28%)
were bereaved. The results grouped by bereavement status for
scenario A, statements 1 to 4 are presented in Table 1 and
scenario B statements 5 to 7 in Table 2. Sixty parents provided at
least one free-text response (18 bereaved, 42 recovered).
Discomfort with Medical Uncertainty
In their free text responses parents commented on the need for
medical research.
‘‘I understand that you are only trying to better the
elimination of meningitis, and in order to do so you have
to carry out these trials’’ [6R]
and made altruistic statements indicating that they wanted to
contribute to such research and the ‘trust’ they needed to place
with the clinical team.
‘‘A parent in this situation has to trust the doctor who is
making the decisions, just as one would rely on a fireman to
put out the flames in one’s house’’ [6B].
However, parents commented that mention of a trial in the
emergency situation would have ‘‘alarmed’’ them [8R]. They
pointed to the powerful and frightening connotations the word
‘trial’ held: ‘‘the word ‘trial’ is a scary term – I don’t think parents would be
happy to have something ‘tried’ out on their child’’ [13R]; ‘‘an experiment
with my child’s life’’ [9R].
Some parents indicated that they equated medical uncertainty
with lack of expertise of the clinical team:
‘‘If we thought […] that the staff did not fully know what
they were doing or administering fluids they did not know
would work, we would have been horrified’’ [3B].
Concerns were also raised that the approach about a trial would
raise questions in their minds about whether a child’s survival was
a clinical team’s primary concern: ‘‘‘playing’ with that person’s life by
conducting a trial’’ [3B]; ‘‘we wanted to see people doing things to help my son
[…] mentioning trials may have alarmed us…’’ [8R] and implied ‘‘that
there might be a better option for your child’’ [5R].
Parents’ clearly wanted to convey the depth of their concerns.
Importantly, however, only 6% (3/67) did not want their child to
be involved in the trial under any circumstances (Table 1:
statement 1). Of these parents, two wrote qualitative responses
indicating that they found it difficult to accept the medical
uncertainty that they associated with the trial. Although the
responses grouped by bereavement status were not statistically
significant, 90% of bereaved parents compared with 65% of
recovered parents would want their child to be included in the trial
(p=0.29). Those in the recovered group gave a greater proportion
of responses in the ‘neither agree nor disagree’ category compared
to bereaved responders (31% compared to 5%).
Is it Acceptable to Defer Consent?
Statement 2 explored whether parents would be willing for their
child to be included in the trial without the trial being explained to
them beforehand.
Sixty-eight percent (45/66) responded positively. Again a higher
percentage of those in the recovered group responded in the
neutral ‘neither agree nor disagree’ category (15% compared to
0%).
70% (47/67) of parents wanted to be informed that their child
had been included in the trial and to be asked for consent as soon
as their child’s condition had stabilized (statement 3). 33% (22/67)
did not want to be told about the trial at any time as long as both
treatments were considered safe (statement 4); 55% (37/67)
disagreed with this. While there were no statistically significant
differences between the groups (p=0.1), a higher proportion of
bereaved responders (33% compared with 14%) felt strongly that
Table 1. Scenario A: If a child of mine had a serious infection and needed emergency fluid treatment.
Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree p-value
Statement 1: I would not want my child to be included in a clinical trial of these two commonly used fluids under any circumstances.
Bereaved 7 (40) 9 (50) 1 (5) 0 (0) 1 (5) 0.29
Recovered 14 (28) 18 (37) 15 (31) 2 (4) 0 (0)
Statement 2: I would be willing for my child to be included in a clinical trial of these two commonly used fluids without the trial being, explained to me
beforehand.
Bereaved 3 (17) 2 (11) 0 (0) 7 (39) 6 (33) 1.00
Recovered 4 (8) 5 (10) 7 (15) 21 (44) 11 (23)
Statement 3: I would like to be told that my child was being included in the trial and to be asked for consent for their information to be included in the trial as soon as
their condition stabilised.
Bereaved 0 (0) 2 (11) 2 (11) 8 (45) 6 (33) 0.68
Recovered 0 (0) 6 (12) 10 (20) 17 (35) 16 (33)
Statement 4: I would not want to be told about the trial at any time, as long as both fluids are considered safe.
Bereaved 6 (33) 6 (33) 2 (11) 3 (17) 1 (6) 0.10
Recovered 7 (14) 18 (37) 6 (12) 7 (14) 11 (23)
Figures are n(%). Missing responses: Question 1:1 bereaved; Question 2:1 bereaved and 1 recovered; Question 3:1 bereaved; Question 4; 1 bereaved.
doi:10.1371/journal.pone.0035982.t001
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opposite extreme, 6% (1/18) bereaved and 23% (11/49) of parents
of recovered children would not want to be told about the trial at
any time.
In the free-text responses one parent of a child who recovered
expressed total disagreement with the concept of deferred consent:
‘‘In that life and death scenario (which we have been in) you
would not want your child’s life to be in a trial. Consent
must and should be granted by parent before any trial is
started.’’ [21R]
Some other parents wrote of the adverse emotional impact that
deferred consent would have: ‘‘if staff had proceeded without asking me
first I would have been very annoyed’’ [16R], while others emphasised
the importance of being honest with parents or implied that
deferred consent involved concealing information ‘‘best not to hide
anything from the parents at all’’ [14R]. Several wrote that the trial
would be ‘blamed’ if the child died or had a poor outcome or
indicated that they would seek legal redress:
‘‘I would have sued anyone that moved if he had died, being
involved in a clinical trial that we knew nothing about’’
[12R].
While acknowledging that many difficult decisions are unavoid-
able in these circumstances, one bereaved parent remarked that
‘‘any explanation and consent is better than none’’ [1B].
Of the 14 parents who disagreed with their child being involved
without the trial being explained beforehand (statement 2) all
agreed with being told their child was being included in the trial
and asked for consent once the child’s condition had stabilised
(statement 3).
Seeking Deferred Consent when a Child has Died
Scenario B considered the profoundly difficult situation in
which a child enrolled in the trial had died prior to the trial being
discussed with the parents and consent sought. While 57% of
parents of children who recovered felt that it would be better not
to tell the bereaved parent about the trial at any time, only 34% of
the bereaved parents felt this way. The majority of bereaved
parents (66%) disagreed with this statement (statement 5, Table 2).
Qualitative responses from the parents who did not want to be
told about the trial at any time indicated that they believed an
explanation of the trial was unnecessary. Clinical equipoise and
the safety and current use of the two treatments featured
prominently in some parents’ justifications of non-disclosure:
‘‘My understanding is that both treatments are currently
used and that there is genuinely no established right or
wrong. Therefore I don’t think the parents would need to
know. Our son died in PICU [Paediatric Intensive Care
Unit] […] and the last thing I would have wanted to be told
was that my son was in a trial […] I don’t feel in a situation
like this it is necessary or desirable to get consent’’. [10B]
‘‘On the basis that these two solutions are both used and
considered safe and presumably she could have conceivably
received either anyway, for me, knowing of the trial would
have led to confusion and questioning which would have
been pointless, negative and detrimental […] the trial is
simply recording the results of her treatment, I would be
happy to be ignorant of this.’’ [19B]
Parents’ comments were motivated by a wish to avoid adding to
the distress of grieving parents. They wrote of how, in the
aftermath of a child’s death, parents were intensely vulnerable and
it was hard for them to be rational. In this context information
about a trial confronted them with knowledge that could be
destructive and exacerbate a parents grief.
Other parents pointed to the disruption for hospitals and
potential for litigation that disclosure could bring:
‘‘They will not ‘‘hear’’ or understand the fact both fluids are
in fact safe […] grief makes people irrational […] people
would consult legal advisors, and in general it would cause
more distress.’’ [17R]
Of the six bereaved parents whose free text responses
indicated they opposed disclosure, in their subsequent comments
about the need to carefully time disclosure, three of these
Table 2. Scenario B: If a child could not be resuscitated and unfortunately died in the emergency department we would want to
tell the parents that their child had been given the fluid as part of a clinical trial of emergency treatments.
Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree p-value
Statement 5: I think in the scenario described it would be better not to tell the bereaved parent/carer about the trial at any time.
Bereaved 6 (33) 6 (33) 0 (0) 1 (6) 5 (28) 0.06
Recovered 7 (14) 11 (23) 3 (6) 8 (16) 20 (41)
Statement 6: I think in the scenario described it would be better to include a child’s records in the trial without immediately asking the bereaved parent/carer, and
seek their consent later at the most appropriate time.
Bereaved 3 (17) 3 (17) 0 (0) 7 (39) 5 (27) 0.59
Recovered 3 (6) 13 (27) 10 (20) 16 (33) 7 (14)
Statement 7: I think in the scenario described it would be better to tell the bereaved parent/carer about the trial and seek their consent before including their child’s
records in the trial.
Bereaved 3 (16) 5 (27) 1 (5) 5 (26) 5 (26) 0.19
Recovered 11 (22) 17 (35) 2 (4) 14 (29) 5 (10)
Figures are n(%). Missing responses: Question 5:1 bereaved; Question 6:1 bereaved.
doi:10.1371/journal.pone.0035982.t002
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might not be completely beyond their contemplation. The
remaining three bereaved parents seemed resolute that they
would not want to be told about the trial at any point. Parents
who were in favour of disclosure also acknowledged the
difficulties that could arise from telling parents about the trial
in such an emotionally charged situation and several sympa-
thised with practitioners and the complexities they would
encounter in disclosing details of the trial.
Timing and Managing the Approach for Deferred
Consent
Statements 6 and 7 considered the inclusion of the child’s
records in the research and the timing of consent. Of the 18
bereaved parents who responded to the survey eight agreed that it
was better to include the child’s records in the trial without
immediately obtaining consent (statement 6) and disagreed with
seeking consent before including the child’s records (statement 7).
Question 8 invited parents to comment about what would be
the most appropriate time for practitioners to explain about the
trial and ask for consent if a child died.
There was no overall consensus regarding the ‘right time to tell’
among the 34 parents who gave free text responses (12 bereaved;
22 recovered), However, recovered parents were rather more
precise in setting a time frame for disclosure compared to their
bereaved counterparts. For example: ‘‘immediately or as soon as
possible’’[12R]; ‘‘as soon as possible after death’’ [16R]; ‘‘at the
time of post mortem’’ [4R]; ‘‘after 3 days once the initial shock has
receded’’ [7R]; ‘‘maybe 2 weeks’’ [20R].
Bereaved parents were less prescriptive: ‘‘as soon as it’s
appropriate’’ [11B]; ‘‘when not too upset to understand’’ [15B]; ‘‘[when]
you’re not too upset, too much you can’t understand’’ [15B]. One bereaved
parent described how nearly six weeks had passed after her child’s
death before she could ‘‘face’’ discussing what had happened with
the consultant [10B]. Another suggested that trial discussion could
be conducted alongside those about organ donation, as she felt
that she had been able to ‘‘take in’’ information at that point [2B],
while another wrote of how she had valued a home-visit from a
Community Nurse Specialist who had explained about her child’s
death in a way she found helpful and sensitive, adding that such a
visit ‘‘a few days after bereavement’’ [18B] could also lend itself to
discussion about the trial.
Question 9 asked ‘What do you think would be the best way to
explain the trial and ask for consent?’ and invited parents to select
one of three options. Forty nine (13 bereaved, 36 recovered)
responded. Fifteen parents (6 bereaved, 9 recovered) selected the
option with the ‘doctor or nurse’, three (recovered) selected
‘written information’, 28 (7 bereaved, 21 recovered) indicated
‘both consultation and written information’. Three parents
indicated ‘neither of these’.
Parents’ additional free text responses indicated they wanted
calm and concise information giving with time to ask questions
and the opportunity for follow-up. Implicit in their responses was
the need for a caring, flexible and responsive approach to
communication.
Discussion
We investigated the acceptability of deferred consent in a
paediatric emergency setting. Results indicated that deferred
consent is acceptable to the majority. Although the survey was
not powered to detect statistically significant differences between
the groups, parents of children who recovered tended to
indicate neutral opinions more frequently. The groups had
differing views regarding disclosure of the trial in the event a
child died before the trial could be discussed. Two thirds of
bereaved parents opposed non-disclosure of the trial compared
to just over a third of parents whose child recovered. While the
sample of bereaved parents was small, in drawing conclusions
about trial disclosure in the context of a child’s death, it could
be argued that greater weight should be given to the responses
of bereaved parents. However, there was a sizeable group of
bereaved parents at each end of the spectrum which reflects the
variety inherent in the experience of bereavement and the
difficulty in developing a policy that will suit the population
concerned. Developing the means to respond to this variety is
the challenge ahead.
While the response rate to this survey was low it is similar to
other postal surveys [17], however non-response bias is unlikely to
be an issue with the percentage of bereaved parents being similar
between responders and non-responders. Cross tabulations of
responses between questions indicated the consistency of responses
suggesting that the responders had understood the survey. Parents
were able to allocate time to discuss, reflect upon and complete
this survey in their own homes. The potential for misinterpreting
information could be exacerbated when encountering these issues
in the crisis of emergency treatment of a child. It is also possible
that parents’ interpretation of the same trial could have been very
different if they had encountered it in a real-life context in which
they had a relationship with the clinical team conducting the trial.
The meanings parents take away from face-to-face discussions
about a trial with caring, committed and compassionate clinicians
are likely to differ from the ones that they had been left with by a
description, received through the post, of a trial being conducted
by researchers they had never met before. Paediatric clinical trials
using deferred consent should conduct qualitative research on the
acceptability of the process during the trial conduct to inform
future trials.
The parents in our survey all had experience of having a
critically ill child and this obliges us to take careful account of their
perspectives, yet few if any are likely to have had experience of
being approached about their child’s participation in a trial in the
emergency setting and it is difficult for anyone to anticipate how
they might respond in such a situation.
In a trial comparing similar interventions to the trial
proposed here, Maitland et al [4], present a modified deferred
consent model in the treatment of children requiring fluid
resuscitation in hospitals in three malaria-endemic African
countries. This involved taking verbal assent from parents at
the point of enrolment, with full written consent being sought
after stabilising the child; but for parents of children who died
prior to full written consent, ethical permission was received to
waiver full consent. In indicating that the majority of parents
would be willing for their child to be included in the trial
without the trial being explained beforehand and the majority
of bereaved parents indicating that they would want to be
informed, our survey’s findings do not support the model used
by Maitland et al [4]. The impact of any assent process on
parents, clinicians and the patient in terms of the assent process
delaying critical treatment should be considered.
Our findings indicate that deferred consent is generally
acceptable in principle to most parents, but also that disclosure
is not something that can be written into ‘one size fits all’
protocols. The death of a child during a trial in which deferred
consent has been used is a uniquely difficult situation, and further
evidence and ethical guidelines are needed regarding the
appropriate handling of this situation.
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of individual parents. In this sense – and it’s by no means a new
concept – communication about trials needs to be practiced as a
process of individualised care, rather than as routinised proce-
dures. Parents value the quality of the relationship with the expert care
team and this will shape their interpretations of the trial [18].
However, practitioners of course need the time, training and
experience to ‘read and respond’ to individual circumstance.
Parents responses indicated the particularly profound complex-
ities involved in seeking deferred consent after a child’s death and
the potential to exacerbate a parent’s grief, a risk that some
thought unnecessary given that both trial treatments were in
current use. Risk proportionate approaches are being applied to
clinical trials governance [19] and questions about how this could
be extended to models of consent should be raised.
Supporting Information
Appendix S1 Postal survey.
(DOC)
Author Contributions
Conceived and designed the experiments: CG SN HH BY. Performed the
experiments: CG SN DS AM HH PW LG CS BY. Analyzed the data: DS
BY AM CG. Contributed reagents/materials/analysis tools: LG. Wrote
the paper: CG SN DS AM HH PW LG CS BY.
References
1. Stephenson T (2006) The Medicines for Children Agenda in the UK. Br J Clin
Pharmacol 61: 716–719.
2. DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENT OF THE
COUNCIL of 4 April 2001 on the approximation of the laws, regulations and
administrative provisions of the Member States relating to the implementation of
good clinical practice in the conduct of clinical trials on medicinal products for
human use. Official Journal of the European Communities L 121, 01/05/2001
P. 0034–0044.
3. Legislation.gov.uk website. Medicines for Human Use (Clinical Trials)
Regulations. S.I. 2004/1031 Available: http://www.opsi.gov.uk/si/si2004/
20041031. Accessed 2012 Apr 10.
4. Maitland K, Molyneux S, Boga M, Kiguli S, Lang T (2011) Use of deferred
consent for severely ill children in a multi-centre phase III trial. Trials 12: 90.
5. Legislation.gov.uk website.The Medicines for Human Use (Clinical Trials)
Amendment (No. 2) Regulations (2006) Available: http://www.opsi.gov.uk/SI/
si2006/20062984.htm. Accessed 2012 Apr 10.
6. Legislation.gov.uk website.The Medicines for Human Use (Clinical Trials) and
Blood Safety and Quality (Amendment) Regulations 2008 941. Available:
http://www.legislation.gov.uk/uksi/2008/941/pdfs/uksi_20080941_en.pdf.
Accessed 2012 Apr 10.
7. Federal register (1996) Protection of human subjects; informed consent-FDA.
Final rule. 61(192): 51498–533.
8. Morrison C, Horwitz I, Carrick M (2009) Ethical and legal issues in emergency
research; Barriers to conducting prospective randomized trials in an emergency
setting. Journal of Surgical Research 157: 115–122.
9. Jansen T, Kompanje E, Druml C, Menon D, Wiedermann C, et al. (2007)
Deferred consent in emergency intensive care research: what if the patient dies
early? Use the data or not? Intensive Care Med 33: 894–900.
10. Jansen TC, Bakker J, Kompanje EJ (2010) Inability to obtain deferred consent
due to early death in emergency research: effect on validity of clinical trial
results. Intensive Care Med 36(11): 1962–5.
11. Nichol G, Powell J, van Ottingham L, Maier R, Rea T, et al. (2006) Consent in
resuscitation trials: Benefit or harm for patients and society? Resuscitation 70:
360–368.
12. National Collaborating Centre for Women’s and Children’s Health (2010)
Bacterial meningitis and meningococcal septicaemia in children. NICE Clinical
Guideline.
13. Braun V, Clarke V (2006) Using thematic analysis in psychology. Qualitative
Research in Psychology 3(2): 77–101.
14. Fereday J, Muir-Cochrane E (2006) Demonstrating Rigor Using Thematic
Analysis: A Hybrid Approach of Inductive and Deductive Coding and Theme
Development. International Journal of Qualitative Methods 5(1).
15. Giacomini M, Ward D (2000) Users’ guides to the medical literature XXIII. Are
the results of the study valid? JAMA 284(3): 357–62.
16. Spencer L, Ritchie J, Lewis J, Dillon L (2003) Quality in qualitative evaluation:
A Framework for Assessing Research Evidence. London: Cabinet Office
(Government Chief Social Researcher’s Office).
17. Culbert A, Davis D (2005) Parental preferences for neonatal resuscitation
research consent: a pilot study. Journal of medical ethics 31: 721–726.
18. Shilling V, Williamson P, Hickey H, Sowden E, Beresford M, et al. (2011)
Communication about children’s clinical trials as observed and experienced:
qualitative study of parents and practitioners. PLoS One 6(7): e21604.
19. Smyth R (2011) A risk adapted approach to the governance of clinical trials.
BMJ 343, d6756.
Deferred Consent in Paediatric Emergency Trials
PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e35982